跳至主要内容
临床试验/NCT04650256
NCT04650256招募中不适用

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

University of Miami2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
2
主要终点
Proportion of patients free of clinically relevant skin toxicities

研究概览

简要总结

The purpose of this research is to study a Chinese herbal Complementary and Alternative Medicine (CAM) product for the temporary relief of pain and itching after radiotherapy (RT). This is an over-the-counter product with 1% menthol as an active ingredient.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female subjects with newly diagnosed breast carcinoma
  • > 18 years of age
  • Post-mastectomy with or without reconstruction
  • Stage II-IIIb with any receptor status
  • All races and ethnicities are eligible
  • Patients must be able to consent in English or Spanish
  • Plan to receive adjuvant radiotherapy to the chest wall +/- regional lymph nodes
  • RT will involve standard fractionation use of 3D conformal or Intensity-modulated RT (IMRT)
  • Willing to sign protocol consent form
  • Patients are allowed to receive adjuvant hormonal therapy and/or targeted therapies such as trastuzumab prior to, during and/or after radiation therapy.
  • Patients may receive chemotherapy before or after radiation therapy

排除标准

  • Prior radiation to the involved breast or chest wall
  • Concurrent chemotherapy
  • Unable or unwilling to sign informed consent
  • Unable to speak English or Spanish
  • Pregnant women
  • Clinical or pathologic stage T4
  • Metastatic disease
  • Connective tissue disorder including Systemic Lupus Erythematosus and Scleroderma

结局指标

主要结局

Proportion of patients free of clinically relevant skin toxicities

时间窗: Up to 18 weeks.

Clinically relevant skin toxicities - Grade 2 with moist desquamation or Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) as evaluated by the treating clinician.

次要结局

  • SD-16 scores(Up to 18 weeks.)
  • Functional Assessment of Cancer Therapy-Breast (FACT-B) scores(Up to 18 weeks.)
  • High-sensitivity C-reactive protein (hsCRP) values(Up to 6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jennifer Hu

Professor

University of Miami

研究点 (2)

Loading locations...

相似试验